Sacituzumab govitecan is a cancer medicine used to treat some types of advanced breast cancer. It is given as an infusion into a vein at a clinic. It works by carrying a strong cancer drug straight to cancer cells that have a certain marker on their surface.
Every report comes from a Lived member, sent anonymously.
Have you tried Trodelvy (Sacituzumab Govitecan) for Triple Negative Breast Neoplasms?
Sacituzumab govitecan, sold as Trodelvy, is a cancer medicine for adults with breast cancer that has spread (metastatic) or has grown locally to a point where surgery cannot remove it. It is given by infusion into a vein at a cancer center or infusion clinic. Its main use is triple-negative breast cancer (TNBC), a type that lacks the estrogen, progesterone and HER2 receptors that many other breast cancer treatments target. For advanced TNBC, it can be the first treatment, either on its own for people who cannot receive immunotherapy, or combined with pembrolizumab (Keytruda), an immunotherapy drug, when a lab test shows the tumor makes enough of a protein called PD-L1. It is also approved for TNBC that has grown after two or more earlier treatments. It is also used for hormone receptor-positive, HER2-negative breast cancer, the most common type, once hormone-based treatments and at least two other courses of treatment for advanced disease have stopped working. This includes tumors labeled "HER2-low". It is not a treatment for HER2-positive breast cancer.
Trodelvy is an antibody-drug conjugate, a design that links a targeting antibody to a chemotherapy drug. The antibody part recognizes Trop-2, a protein found on the surface of most breast cancer cells. Once the antibody attaches, the cancer cell pulls the whole molecule inside, where the chemotherapy is released. The chemotherapy is SN-38, the active form of an older drug called irinotecan. SN-38 blocks an enzyme (topoisomerase I) that cells need to repair their DNA as they divide, so the damaged cancer cells die. Some SN-38 also reaches healthy fast-dividing cells, especially in the bone marrow and the lining of the gut. That is why low white blood cell counts and diarrhea are its main side effects, even though the drug is aimed at cancer cells.
Trodelvy is given as an intravenous (IV) infusion on days 1 and 8 of a three-week cycle, so two treatment weeks are followed by a week off. The dose is based on body weight. The first infusion takes about three hours; later ones usually take one to two hours if the first went smoothly. The team watches for reactions during each infusion and for at least 30 minutes afterward. Before each dose, people usually receive medicines to prevent infusion reactions and nausea. Many also get a white blood cell booster (G-CSF, such as filgrastim injections), especially those at higher risk of infection. Blood counts are checked before treatments, and a dose may be delayed or lowered if counts are too low or side effects are hard to manage. Once lowered, the dose is not raised again. You will usually go home with anti-nausea medicine and loperamide (Imodium), an anti-diarrhea medicine, along with written instructions on when to use them and when to call. Treatment continues as long as the cancer is controlled and side effects are manageable. When given with pembrolizumab, the pembrolizumab is stopped after about two years.
The most common effects are nausea, diarrhea, tiredness and hair loss, which affects about half of people. Constipation, vomiting, poor appetite and stomach pain are also common. Blood tests often show low white blood cells and low red blood cells (anemia), which can add to tiredness. Trodelvy carries the FDA's strongest (boxed) warning for two problems. The first is neutropenia, a drop in the white blood cells that fight infection. It can be severe and has been fatal, and it can begin in the first cycle. Call your care team right away for a fever, chills or any other sign of infection, even if you feel only mildly unwell. The second is severe diarrhea, which can lead to dehydration and kidney problems. Call your care team the first time diarrhea starts during treatment, so they can check for infection and tell you how to start loperamide. Call right away for black or bloody stools, dizziness or feeling faint, being unable to keep fluids down, or diarrhea that is not under control within 24 hours. Allergic and infusion reactions are possible during or after an infusion. Tell the team at once about itching, hives, flushing, chills, wheezing or swelling. If swelling of the face, lips, tongue or throat or serious trouble breathing starts after you leave the clinic, call 911.
Trodelvy can harm an unborn baby. Women who could become pregnant should use effective birth control during treatment and for six months after the last dose, and men with partners who could become pregnant should use it for three months after. Tell your team promptly if you or your partner becomes pregnant. Do not breastfeed during treatment or for one month after the last dose. Trodelvy may also affect fertility, which is worth discussing before starting if future pregnancy matters to you. The body clears SN-38 using a liver enzyme called UGT1A1. Some people inherit a gene variant (two copies of a version called UGT1A1*28) that makes this enzyme less active. They are more likely to have severe neutropenia and anemia, often earlier in treatment, so their team watches them more closely. Medicines that block or speed up UGT1A1 can raise or lower SN-38 levels and should be avoided, so give your oncology team and pharmacist a full list of medicines and supplements. Trodelvy must not be combined with or swapped for irinotecan or other medicines containing SN-38. People who have had a severe allergic reaction to Trodelvy should not receive it again.
Treatment follows a steady routine: infusion visits on two of every three weeks, blood counts before doses, and scans every couple of months to see whether the cancer is shrinking, stable or growing. Side effects are usually most noticeable in the days after each infusion and in the first cycles, and many people need at least one dose delay or reduction along the way. Trodelvy treats advanced breast cancer but is not expected to cure it. In large trials, it kept cancer under control longer than standard chemotherapy, and in previously treated disease people lived longer on average. In triple-negative cancer treated after earlier therapies, the time before the cancer grew was about three times as long as with standard chemotherapy. In hormone receptor-positive cancer, average survival was about three months longer. Results vary widely: some people respond for many months, while in others the cancer grows despite treatment, and the team will then discuss other options.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Trodelvy (Sacituzumab Govitecan), what you've noticed, or ask the community a question.